Large-scale testing (Phase 3)Study completedNCT01941329
What this trial is testing
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
Who this might be right for
High Risk Proliferative Diabetic Retinopathy
Association for Innovation and Biomedical Research on Light and Image 94